NL-OMON40620已完成2 期
A double blind, randomized, placebo controlled, cross-over study to validate the predictive power of the demarcation formula for Lybrido and Lybridos efficacy in women with female sexual interest/arousal disorder, in the domestic situation. - A study to validate the demarcation formula for Lybrido and Lybridos.
Companion Diagnostics BV0 个研究点目标入组 150 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Provision of written informed consent
- •2. Females between 18 and 70 years of age, inclusive, pre or postmenopausal, with FSIAD (comorbidity with female orgasmic disorder [FOD]; only as secondary diagnosis) is allowed. The diagnosis of FSIAD will be established by a trained health care professional
- •3. Be involved in a stable, communicative, monogamous relationship and have a sexually functional partner who will be at home for a large part of the study duration
- •4. Healthy with normal medical history, physical examination, laboratory values, and vital signs; exceptions may be made if the investigator considers an abnormality to be clinically irrelevant
- •5. Use of highly effective contraception
排除标准
- •1. Any underlying cardiovascular condition, including unstable angina pectoris, that would preclude sexual activity;
- •2. Systolic blood pressure >= 140 mmHg and/or diastolic blood pressure >= 90 mmHg (supine blood pressure). For subjects >= 60 years old and without diabetes mellitus, familial hypercholesterolemia, or cardiovascular disease: systolic blood pressure >= 160 mmHg and/or diastolic blood pressure >= 90 mmHg;
- •3. Systolic blood pressure <= 90 mmHg and/or diastolic blood pressure <= 50 mmHg (supine blood pressure);
- •4. Use of any contraceptive containing anti-androgens (e.g. Cyproteron acetate) or (anti)androgenic progestogens (drospirenone, dienogest, chlormadinone acetate and norgestrel);
- •5. Use of any contraceptive or hormone replacement therapy (HRT) containing more than 50 µg/day of estrogen;
- •6. Pregnancy or intention to become pregnant during this study (Note: A urine pregnancy test will be performed in all women of child bearing potential prior to the administration of study medications);
- •7. Lactating or delivery in the previous 6 months prior to signing Informed Consent Form;
- •8. History of bilateral oophorectomy;
- •9. Other unexplained gynecological complaints, such as clinically relevant abnormal uterine bleeding patterns;
- •10. Perimenopausal status (cycle shortening/irregular menstrual bleeding in the last 12 consecutive months and/or occurrence of vasomotor symptoms (e.g. hot flashes, night sweating) and/or FSH levels (>40 IU/L) for women from age 40 onwards; in women with a history of hysterectomy perimenopausality can be assessed by FSH levels (> 40 IU/L) and/or vasomotor symptoms);
- •11. Liver and/or renal insufficiency (aspartate aminotransferase, alanine aminotransferase and gamma glutamyltransferase > 3 times the upper limit of normal and/or estimated glomerular filtration rate (eGFR) < 60.00 mL/min based on the Cockcroft Gault formula)
- •12. Any current endocrine disease or endocrinopathy (e.g. uncontrolled thyroid function) as determined by medical history, basic physical examination and/or laboratory values significantly outside normal range of the central laboratory; or uncontrolled diabetes mellitus (HbA1c > 7.5%)
- •13. Free- and/or total testosterone levels outside the upper limit of the reference range of the central laboratory;
- •14. Any current clinically relevant neurological disease which, in the opinion of the investigator, would compromise the validity of study results or which exclude from use of sildenafil, buspirone and/or testosterone;
- •15. History of hormone dependent malignancy (including all types of breast cancer);
- •16. Positive test result for immunodeficiency virus, hepatitis B, or hepatitis C (acute and chronic hepatitis infection);
- •17. History of (childhood) sexual abuse that, in the opinion of the investigator, could result in negative psychological effects when testosterone is administered;
- •18. (Psychotherapeutic and/or pharmacological treatment for) a psychiatric disorder (other than those under inclusion criterion 6) that, in the opinion of the investigator, would compromise the validity of study results or which could be a contraindication for sildenafil, buspirone and/or testosterone use;
- •19. Current psychotherapeutic treatment for female sexual dysfunction;
- •20. Current genito-pelvic pain/penetration disorder according to the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM 5).
- •21. A substa
研究者
相似试验
尚未招募
4 期
A double blind, randomized, placebo controlled, cross-over trial investigating the effect of High Amylose Maize Starch (HAMS) supplementation on fecal microbiological and inflammatory outcomes in individuals with Cystic Fibrosis and Healthy Volunteers.Cystic FibrosisACTRN12618000283279Mater Misericordiae Ltd20
招募中
不适用
A study to validate the demarcation formula for Lybrido and LybridosFSIADNL-OMON28721Companion Diagnostics BV150
进行中（未招募）
不适用
ybrido(s) and SSRI's@homeEUCTR2013-001966-40-NLCompanion Diagnostics BV
进行中（未招募）
1 期
Trial on the effectiveness of Fampridine medication for upper limb function in people with MS.MedDRA version: 14.1Level: PTClassification code 10063401Term: Primary progressive multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMultiple sclerosisMedDRA version: 14.1Level: PTClassification code 10053395Term: Progressive multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.1Level: PTClassification code 10063400Term: Secondary progressive multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2011-002561-38-IESt. Vincent's University Hospital80
已完成
不适用
A double blind, placebo controlled, randomized, cross-over study to assess the effects of polydextrose on appetite suppression and its mechanisms of action in healthy women with a normal weight and overweight female participants10003018NL-OMON41091TNO32